Loading…
Loading…
EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its financial results for the second quarter 2027. The Company will report its financial results prior to market open that same morning. Investor Conference Call Details DA.
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.
NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.
Curaleaf TodayCURLFCuraleaf$7.80 +0.17 (+2.26%) As of 02:38 PM Eastern52-Week Range$5.40▼$15.15Price Target$6.00Add to WatchlistCuraleaf Holdings, Inc. OTCMKTS: CURLF is aggressively maneuvering to absorb Aurora Cannabis Inc. NASDAQ: ACB, leveraging an estimated 217% ex-cash premium to force a shareholder reckoning and bypass an entrenched board.
NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders.
Curaleaf recently raised its offer for Aurora Cannabis to $5. Aurora is reviewing the bid and will make a recommendation to shareholders on what to do.
BeOne Medicines (NASDAQ: ONC - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Volatility and Risk BeOne Medicines has a beta
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.